Login / Signup

Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.

M BiagiA ShajeeA VialichkaM JurkovicX TanEric Wenzler
Published in: Antimicrobial agents and chemotherapy (2020)
The Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.
Keyphrases
  • gram negative
  • multidrug resistant
  • drug resistant
  • genetic diversity
  • acinetobacter baumannii
  • klebsiella pneumoniae
  • escherichia coli
  • risk assessment
  • climate change
  • replacement therapy